• Coty applies for listing on the Paris Stock Exchange
  • Société Générale completes 440.5 M euros share buyback.
  • FDA grants priority review to Dupixent (Sanofi) for the treatment of eosinophilic esophagitis in children aged 1 to 11.
  • Imperial Brands fell 6% yesterday after The Guardian reported that British Prime Minister Rishi Sunak is considering banning cigarettes for the next generation.
  • ASM International raises its sales target for 2025.
  • Verbio reports lower profits and a cautious outlook.
  • ASOS reported a 10% drop in annual sales, but said it was profitable in the last quarter and that its turnaround plan was progressing.
  • CRH will allocate $10 billion to dividends and share buybacks over the next five years, according to its CEO.
  • DWS(Deutsche Bank) pays $25 million to the US Securities and Exchange Commission to settle a lawsuit.
  • Nissan boss Makoto Uchida assures that there will be "no turning back" on electric cars.
  • Ford halts construction of a $3.5 billion battery plant in Michigan, due to doubts about the site's competitiveness.
  • Evonik plans to reorganize by spinning off certain assets.
  • Spotify unveils AI-powered voice translation feature.
  • Eckert & Ziegler wins a major US contract.
  • Cofinimmo divests two nursing homes in Belgium.
  • Tesla and European carmakers exporting from China to the European Union (EU) will be part of the bloc's investigation into whether China's electric vehicle industry is receiving illegal subsidies, the Financial Times reported on Tuesday.
  • The production stoppage at Apple supplier Pegatron's Indian iPhone factory is expected to last until Wednesday, if not longer, as authorities investigate a fire at the plant. Meanwhile, European industry chief Thierry Breton on Tuesday called on Apple CEO Tim Cook to open up his software ecosystem to rivals.
  • Envestnet - The wealth management fintech was down 1.5% after the close following the replacement of its CFO.
  • Madrigal Pharmaceuticals - The pharmaceutical manufacturer falls 5.27% in after-hours trading as its Chief Commercial Officer, Remy Sukhija, who has held the position since April 2020, leaves the group, according to a regulatory filing.
  • The Food and Drug Administration (FDA) expressed concerns on Monday about the safety and efficacy of BrainStorm Cell Therapeutics' treatment for amyotrophic lateral sclerosis. The group lost 40.4% before the opening.